Morgan Stanley analyst David Bailey downgraded ResMed (NYSE: RMD) from Overweight to Equalweight with a price target of $230.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades